TokenPost·
FDA Extends Agios’ Mitapivat Review for Sickle Cell Disease by Three Months
The updated PDUFA goal date is Feb. 1, 2027, moved from Nov. 1, 2026. The FDA accepted the application for Priority Review in July.
More news
- TokenPostIntuit Executive Says Lending Nearly Reached $7 Billion in Fiscal 2026
- TokenPostBinance Co-CEO Targets Sunday Withdrawal Restart After Hack
- Crypto BriefingCrypto stocks plunge harder than Bitcoin as BTC sits 39% below its peak
- TokenPostPelthos Therapeutics Shares Fall About 35% After Castle Creek Merger Deal
- CryptoSlateBOJ will more than double stock-fund sales from January
- CryptopolitanIsrael extradites Nomad exploit suspect after rejecting 'code is law' defense